TPIV - TapImmune, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
10.13
-0.27 (-2.60%)
At close: 4:00PM EDT

10.10 -0.03 (-0.30%)
After hours: 7:18PM EDT

Stock chart is not supported by your current browser
Previous Close10.40
Open10.37
Bid9.60 x 800
Ask10.25 x 1000
Day's Range10.05 - 10.92
52 Week Range2.58 - 13.55
Volume177,665
Avg. Volume587,901
Market Cap129.33M
Beta0.28
PE Ratio (TTM)N/A
EPS (TTM)-1.18
Earnings DateMay 29, 2018 - Jun 4, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.50
Trade prices are not sourced from all markets
  • American City Business Journalslast month

    This Jacksonville company's stock is surging as the market sees there's "no competitor"

    TapImmune has created a space all its own in the world of cancer-fighting therapies and is priced well-below its value, according to an analyst.

  • TapImmune Stock: Why It Spiked 84% Last Week
    Market Realistlast month

    TapImmune Stock: Why It Spiked 84% Last Week

    TapImmune (TPIV) stock saw an ~84.1% hike during the week of June 1–8. On June 8, it closed at $9, which was a 249% growth from its 52-week low of $2.58 on April 23. On June 5 and June 6, TPIV stock had consistent growth of ~11.3% and ~11.2%, respectively. On June 8, TapImmune entered into security purchase agreements with some institutional and accredited investors related to the private placement of its equity securities.

  • ACCESSWIRElast month

    Major Regulatory Changes & Recent FDA Win Could Create a 400%+ Gain For Investors Holding This Unknown Stock

    Remote patient monitoring, through smaller cheaper technology, is transforming medical care in the U.S. Cardiac care is a major beneficiary, and now major government agencies are signalling that this sector could be a top priority in the coming years. New medical device from Biotricity (BTCY) could shake up a handful of existing companies in cardiac remote monitoring, as their new device has some clear improvements over older technology. With revenue and new product announcements this year, BTCY could move significantly higher in 2018 and 2019.

  • ACCESSWIRElast month

    Today’s Research Reports on Stocks to Watch: TapImmune and Intercept Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / June 11, 2018 / TapImmune and Intercept Pharmaceuticals were two biotech stocks heading higher in Friday trading. Intercept didn't have any particularly remarkable news but did announce that management would be presenting this Tuesday at the Goldman Sachs 39th Annual Global Healthcare Conference.

  • TapImmune Announces Pricing of $70 Million Private Placement
    PR Newswirelast month

    TapImmune Announces Pricing of $70 Million Private Placement

    JACKSONVILLE, Fla., June 8, 2018 /PRNewswire/ -- TapImmune Inc. (TPIV), a clinical-stage immuno-oncology company, today announced that it has entered into security purchase agreements with certain institutional and accredited investors in connection with a private placement of its equity securities. The private placement will be led by New Enterprise Associates (NEA) with participation from Aisling Capital and Perceptive Advisors, among other new and existing investors. The private placement is expected to be completed concurrently with the closing of the proposed merger between TapImmune Inc. and Marker Therapeutics, Inc., which was previously announced on May 15, 2018.

  • Benzingalast month

    TapImmune Poised To Become A Cell Therapy Leader, WBB Securities Says In Upgrade

    TapImmune recently announced a merger agreement and reorganization with privately held Marker Therapeutics. The company then announced the formation of a Scientific Advisory Board after the close of the proposed merger May 16.

  • PR Newswire2 months ago

    TapImmune to Present at the Jefferies 2018 Global Healthcare Conference

    JACKSONVILLE, Fla. , May  31, 2018 /PRNewswire/ --  TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, today announced that its President and CEO, Peter L. Hoang , will present at ...

  • PR Newswire2 months ago

    TapImmune to Present at 2018 Sachs Associates Immuno-Oncology BD&L and Investment Forum

    JACKSONVILLE, Fla. , May 30, 2018 /PRNewswire/ --  TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, today announced that its President and CEO, Peter Hoang , will participate in ...

  • TapImmune to Host Investor Webinar on Thursday, May 24th to Discuss Proposed Merger with Marker Therapeutics and Its Transformational T Cell Therapy Platform
    PR Newswire2 months ago

    TapImmune to Host Investor Webinar on Thursday, May 24th to Discuss Proposed Merger with Marker Therapeutics and Its Transformational T Cell Therapy Platform

    JACKSONVILLE, Fla. , May 23, 2018 /PRNewswire/ -- TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, announced today that Peter Hoang , President and CEO, will host a video webinar ...

  • TapImmune Expands Scientific Advisory Board with Cancer Immunotherapy Pioneers James P. Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., from the MD Anderson Cancer Center
    PR Newswire2 months ago

    TapImmune Expands Scientific Advisory Board with Cancer Immunotherapy Pioneers James P. Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., from the MD Anderson Cancer Center

    JACKSONVILLE, Fla., May 22, 2018 /PRNewswire/ -- TapImmune Inc. (TPIV), a clinical-stage immuno-oncology company, today announced that it has expanded its recently formed Scientific Advisory Board (SAB), which will become effective in conjunction with the proposed merger between the Company and Marker Therapeutics, Inc., and will support the continued clinical development of the Company's transformative, non-genetically engineered, multi-antigen T cell therapy platform. The new SAB members include leading experts from the University of Texas MD Anderson Cancer Center. James P. Allison, Ph.D., is a globally recognized tumor immunologist whose research led to the clinical development of the first FDA-approved cancer immunotherapy, ipilimumab (Yervoy®).

  • TapImmune Creates Scientific Advisory Board to Support Clinical Development of Multi-Antigen Cell Therapy Platform
    PR Newswire2 months ago

    TapImmune Creates Scientific Advisory Board to Support Clinical Development of Multi-Antigen Cell Therapy Platform

    JACKSONVILLE, Fla., May 16, 2018 /PRNewswire/ -- TapImmune Inc. (TPIV), a clinical-stage immuno-oncology company, today announced that it has assembled a Scientific Advisory Board (SAB) composed of leading experts in the field of immuno-oncology and cell therapy and that will become effective in conjunction with the proposed merger between the Company and Marker Therapeutics, Inc. The goal of the SAB will be to support the continued clinical development of the Company's transformative, non-genetically engineered, multi-antigen T cell therapy platform. Foundational members of the SAB include senior medical scientists from the Center for Cell and Gene Therapy at Baylor College of Medicine, including its founding Director and former President of the American Society for Gene and Cell Therapy (ASGCT) and of the International Society for Cell Therapy, Malcolm K. Brenner, M.D., Ph.D. Joining Dr. Brenner are colleagues Helen E. Heslop, M.D., D.Sc.

  • TapImmune to Host Investor Breakfast to Discuss Proposed Merger with Marker Therapeutics
    PR Newswire2 months ago

    TapImmune to Host Investor Breakfast to Discuss Proposed Merger with Marker Therapeutics

    Live Audio Webcast Scheduled for May 17th at 8:00 a.m. CT JACKSONVILLE, Fla. , May 15, 2018 /PRNewswire/ -- TapImmune Inc. (NASDAQ: TPIV), a leading clinical-stage immuno-oncology company, today announced ...

  • Merger takes Jacksonville immunotherapy company to Houston
    American City Business Journals2 months ago

    Merger takes Jacksonville immunotherapy company to Houston

    A merger announced today will take a publicly-traded, Jacksonville company out of state.

  • TapImmune and Marker Therapeutics Announce Entry into Merger Agreement, Creating a Transformational Immuno-Oncology Platform
    PR Newswire2 months ago

    TapImmune and Marker Therapeutics Announce Entry into Merger Agreement, Creating a Transformational Immuno-Oncology Platform

    JACKSONVILLE, Fla., May 15, 2018 /PRNewswire/ -- TapImmune Inc. (TPIV) ("TapImmune") today announced that it has entered into a definitive merger agreement to acquire Marker Therapeutics, Inc. ("Marker"), a privately-held clinical-stage developer of a transformative, non-genetically engineered, multi-antigen T cell therapy platform. The proposed transaction will be a merger-of-equals under which the stockholders of TapImmune and Marker will each own approximately 50% of the combined company, prior to any issuances of additional shares in a contemplated financing.

  • PR Newswire2 months ago

    TapImmune to Present at 2018 NYC Oncology Investor Conference

    JACKSONVILLE, Fla. , May 7, 2018 /PRNewswire/ -- TapImmune Inc. (NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced ...

  • TapImmune to Present at 2018 Disruptive Growth & Healthcare Conference
    PR Newswire3 months ago

    TapImmune to Present at 2018 Disruptive Growth & Healthcare Conference

    JACKSONVILLE, Fla. , May 1, 2018 /PRNewswire/ -- TapImmune Inc. (NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced ...

  • ACCESSWIRE3 months ago

    Blog Exposure - GTx Completed Patient Enrollment Several Months Ahead in the Phase-2 Clinical Trial of Enobosarm in SUI

    Stock Monitor: TapImmune Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 11, 2018 / Active-Investors.com has just released a free research report on GTx, Inc. (NASDAQ: GTXI ). If you want access ...

  • TapImmune Provides Fourth Quarter and Year-End 2017 Corporate and Clinical Update
    PR Newswire3 months ago

    TapImmune Provides Fourth Quarter and Year-End 2017 Corporate and Clinical Update

    Conference Call and Live Audio Webcast Scheduled for Today, April 5, 2018, at 4:30 p.m. ET JACKSONVILLE, Fla. , April 5, 2018 /PRNewswire/ -- Recent Corporate and Clinical Developments: Published long-term ...

  • TapImmune to Provide Fourth Quarter and Full Year 2017 Business Update Conference Call and Webcast
    PR Newswire4 months ago

    TapImmune to Provide Fourth Quarter and Full Year 2017 Business Update Conference Call and Webcast

    Company to Provide Corporate and Clinical Overview on Thursday, April 5, 2018, 4:30pm ET JACKSONVILLE, Fla. , March 29, 2018 /PRNewswire/ --   TapImmune Inc. (NASDAQ: TPIV ), a leading clinical-stage immuno-oncology ...

  • ACCESSWIRE4 months ago

    TapImmune to Present at The MicroCap Conference

    NEW YORK, NY / ACCESSWIRE / March 28, 2018 / TapImmune Inc. (NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced that ...

  • TapImmune Announces Publication of Clinical Trial Results for the TPIV200 Cancer Vaccine in Clinical Cancer Research
    PR Newswire4 months ago

    TapImmune Announces Publication of Clinical Trial Results for the TPIV200 Cancer Vaccine in Clinical Cancer Research

    JACKSONVILLE, Fla., March 15, 2018 /PRNewswire/ -- TapImmune Inc. (TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced the publication of clinical data from a Phase 1 trial of TPIV200, the company's multi-epitope T-cell vaccine targeting Folate Receptor Alpha (FRa) in patients with ovarian and breast cancer. The study by Kalli, Block, et al., titled, "Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients," will be published in the leading peer-reviewed oncology journal Clinical Cancer Research and will be available online today.

  • TapImmune to Present at Two Upcoming Investor Conferences
    PR Newswire4 months ago

    TapImmune to Present at Two Upcoming Investor Conferences

    JACKSONVILLE, Fla. , March 14, 2018 /PRNewswire/ --  TapImmune Inc. (NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced ...

  • PR Newswire5 months ago

    TapImmune to Participate in Two Upcoming Investor Conferences

    JACKSONVILLE, Fla. , Feb. 6, 2018 /PRNewswire/ --  TapImmune Inc. (NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced ...

  • TapImmune to Present at Biotech Showcase™ 2018
    PR Newswire6 months ago

    TapImmune to Present at Biotech Showcase™ 2018

    JACKSONVILLE, Fla. , Jan. 3, 2018 /PRNewswire/ -- TapImmune Inc. (NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced ...